Trial Profile
Clinical study of apatinib combined with oxaliplatin in the treatment of platinum - resistant recurrent ovarian cancer .
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Oxaliplatin
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Nov 2017 New trial record